瑞舒伐他汀与西他列汀药物相互作用导致横纹肌溶解：一例报告
Rosuvastatin-Induced Rhabdomyolysis as a Result of Drug Interaction With Sitagliptin: A Case Report.
作者信息
Atapour Abdolamir, Momenzadeh Mahnaz, Panahishokouh Mahsa, Badri Shirinsadat
机构信息
Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran.
出版信息
Clin Med Insights Case Rep. 2024 Sep 2;17:11795476241274162. doi: 10.1177/11795476241274162. eCollection 2024.
Abstract
Rhabdomyolysis was not reported in clinical trials with Sitagliptin alone. However, several reports in the literature on rhabdomyolysis resulted from the interaction between statins and Sitagliptin. In patients with type 2 diabetes and hyperlipidemia, it is expected to co-prescribe statins and Sitagliptin. Herein, we report the case of a 64-year-old woman with rhabdomyolysis should be caused by a drug-drug interaction between Rosuvastatin and Sitagliptin. The patient denied any history of weakness or myalgia during past medical assessments.
摘要
在单独使用西他列汀的临床试验中未报告横纹肌溶解症。然而，文献中有几篇关于横纹肌溶解症的报道是由他汀类药物与西他列汀之间的相互作用引起的。在2型糖尿病和高脂血症患者中，预计会联合使用他汀类药物和西他列汀。在此，我们报告一例64岁女性因瑞舒伐他汀与西他列汀之间的药物相互作用导致横纹肌溶解症的病例。该患者在过去的医学评估中否认有任何虚弱或肌痛病史。
相似文献
1
Rosuvastatin-Induced Rhabdomyolysis as a Result of Drug Interaction With Sitagliptin: A Case Report.瑞舒伐他汀与西他列汀药物相互作用导致横纹肌溶解：一例报告
Clin Med Insights Case Rep. 2024 Sep 2;17:11795476241274162. doi: 10.1177/11795476241274162. eCollection 2024.
2
Sitagliptin and Simvastatin Interaction Causing Rhabdomyolysis and AKI.西他列汀与辛伐他汀相互作用导致横纹肌溶解和急性肾损伤。
Case Rep Med. 2019 Feb 26;2019:2601537. doi: 10.1155/2019/2601537. eCollection 2019.
3
Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.由西他列汀与洛伐他汀潜在相互作用引起的横纹肌溶解症。
Pharmacotherapy. 2009 Mar;29(3):352-6. doi: 10.1592/phco.29.3.352.
4
Acute Kidney Injury and Quadriparesis Due to Rosuvastatin Induced Rhabdomyolysis- A Case Report.瑞舒伐他汀诱导横纹肌溶解导致急性肾损伤和四肢瘫——病例报告
J Clin Diagn Res. 2015 May;9(5):OD08-9. doi: 10.7860/JCDR/2015/12117.5909. Epub 2015 May 1.
5
Rhabdomyolysis and AKI with Atorvastatin and Sitagliptin Use in the Setting of Low 25-Hydroxyvitamin D Levels.在 25-羟维生素 D 水平低的情况下使用阿托伐他汀和西他列汀导致横纹肌溶解和急性肾损伤。
J Gen Intern Med. 2017 Oct;32(10):1156-1159. doi: 10.1007/s11606-017-4115-x. Epub 2017 Jul 13.
6
Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use.与使用西他列汀和辛伐他汀相关的肾衰竭和横纹肌溶解症。
Diabet Med. 2008 Oct;25(10):1229-30. doi: 10.1111/j.1464-5491.2008.02536.x.
7
Rosuvastatin-Induced Myopathy: A Case Series.瑞舒伐他汀所致肌病：病例系列
Cureus. 2024 Aug 5;16(8):e66180. doi: 10.7759/cureus.66180. eCollection 2024 Aug.
8
Rhabdomyolysis and acute kidney injury potentiated by a drug-drug interaction between cyclosporine, leflunomide, and rosuvastatin in a kidney transplant recipient: A missed opportunity for pharmacist involvement.环孢素、来氟米特和瑞舒伐他汀药物相互作用致肾移植受者横纹肌溶解和急性肾损伤：错失药师参与机会。
J Am Pharm Assoc (2003). 2024 May-Jun;64(3):102016. doi: 10.1016/j.japh.2024.01.012. Epub 2024 Jan 23.
9
Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation.
Drug Metabol Drug Interact. 2009;24(1):83-7. doi: 10.1515/dmdi.2009.24.1.83.
10
Rosuvastatin-induced rhabdomyolysis due to medication errors.因用药错误导致的瑞舒伐他汀引起的横纹肌溶解症。
Ceska Slov Farm. 2020 Spring;69(2):100-102.
引用本文的文献
1
Rhabdomyolysis triggered by initiation of tirzepatide.替尔泊肽起始治疗引发的横纹肌溶解症。
Diabetol Int. 2025 Jun 11;16(3):591-594. doi: 10.1007/s13340-025-00825-x. eCollection 2025 Jul.
本文引用的文献
1
Rosuvastatin and Colchicine combined myotoxicity: lessons to be learnt.瑞舒伐他汀与秋水仙碱联合肌毒性：值得吸取的教训。
CEN Case Rep. 2021 Nov;10(4):570-575. doi: 10.1007/s13730-021-00598-7. Epub 2021 May 24.
2
DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.二肽基肽酶-4 抑制剂联合降脂药物与严重肌肉损伤风险：一项基于 2 型糖尿病患者全国队列的巢式病例对照研究。
Drug Saf. 2020 Aug;43(8):767-774. doi: 10.1007/s40264-020-00936-1.
3
Risk of Myopathy Associated With DPP-4 Inhibitors in Combination With Statins: A Disproportionality Analysis Using Data From the WHO and French Spontaneous Reporting Databases.二肽基肽酶-4抑制剂与他汀类药物联合使用相关的肌病风险：一项使用世界卫生组织和法国自发报告数据库数据的不成比例分析。
Diabetes Care. 2017 Mar;40(3):e27-e29. doi: 10.2337/dc16-1822. Epub 2016 Dec 20.
4
Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice.超越肌肉破坏：横纹肌溶解症临床实践的系统评价
Crit Care. 2016 Jun 15;20(1):135. doi: 10.1186/s13054-016-1314-5.
5
Acute-onset rhabdomyolysis secondary to sitagliptin and atorvastatin interaction.西他列汀与阿托伐他汀相互作用继发急性横纹肌溶解症。
Int J Gen Med. 2016 Apr 29;9:103-6. doi: 10.2147/IJGM.S98543. eCollection 2016.
6
Rhabdomyolysis: pathogenesis, diagnosis, and treatment.横纹肌溶解症：发病机制、诊断与治疗
Ochsner J. 2015 Spring;15(1):58-69.
7
Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics.西他列汀/辛伐他汀：首款用于治疗2型糖尿病和高胆固醇血症的复方片剂——其特性综述
Vasc Health Risk Manag. 2015 Feb 11;11:125-32. doi: 10.2147/VHRM.S79198. eCollection 2015.
8
Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review.横纹肌溶解所致急性肾损伤及肾脏替代治疗：一项批判性综述
Crit Care. 2014 May 28;18(3):224. doi: 10.1186/cc13897.
9
Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.ABCB1 多态性和阿托伐他汀对健康志愿者中西格列汀药代动力学的影响。
Eur J Clin Pharmacol. 2013 Jul;69(7):1401-9. doi: 10.1007/s00228-013-1475-y. Epub 2013 Feb 14.
10
The effects of simvastatin on the pharmacokinectics of sitagliptin.辛伐他汀对西他列汀药代动力学的影响。
J Popul Ther Clin Pharmacol. 2012;19(3):e356-60. Epub 2012 Oct 11.
Zotero 插件